Head to Head Contrast: Alpha Teknova (NASDAQ:TKNO) vs. OmniAb (NASDAQ:OABI)

OmniAb (NASDAQ:OABI) and Alpha Teknova (NASDAQ:TKNO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares OmniAb and Alpha Teknova”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$38.46 million	17.54	-$64.78 million	($0.36)	-12.94
Alpha Teknova	$43.70 million	7.89	-$17.26 million	($0.31)	-20.71

Alpha Teknova has higher revenue and earnings than OmniAb. Alpha Teknova is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

72.1% of OmniAb shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 9.8% of OmniAb shares are owned by company insiders. Comparatively, 13.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for OmniAb and Alpha Teknova, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1	0	3	0	2.50
Alpha Teknova	1	1	4	0	2.50

OmniAb presently has a consensus price target of $11.50, suggesting a potential upside of 146.78%. Alpha Teknova has a consensus price target of $8.75, suggesting a potential upside of 36.29%. Given OmniAb’s higher probable upside, equities research analysts clearly believe OmniAb is more favorable than Alpha Teknova.

Volatility & Risk

OmniAb has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.

Profitability

This table compares OmniAb and Alpha Teknova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
Alpha Teknova	-38.37%	-24.94%	-16.53%

Summary

Alpha Teknova beats OmniAb on 7 of the 13 factors compared between the two stocks.

About OmniAb

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

About Alpha Teknova

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.